Search

Displaying results 1951 - 1960 of 4588 in total
  1. Drug

    Disaccharide tripeptide glycerol dipalmitoyl

    go.drugbank.com/drugs/DB15423
    Investigational

    Disaccharide tripeptide glycerol dipalmitoyl is under investigation in clinical trial NCT00003667 (Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma).

  2. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Clinical studies by the Parkinson's Study Group show that very high doses of an antioxidant called Coenzyme Q (which Mitoquinone effectively targets into mitochondria) appear to slow the progression of

  3. Drug

    Tenofovir disoproxil

    go.drugbank.com/drugs/DB00300
    ApprovedInvestigational

    Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name _Viread_, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase

  4. Drug

    Cinnamaldehyde

    go.drugbank.com/drugs/DB14184
    Approved

    Cinnamaldehyde is a naturally occurring flavonoid that gives the spice cinnamon its flavour and odour. It occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to...

  5. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available. … [L2615] Dandruff is a common scalp disease affecting >40% of the world's adult population, and may be caused by fungi such as _Malassezia globosa_ and _M. restricta_.[A32162]

  6. Drug

    DTS-201

    go.drugbank.com/drugs/DB06071
    Experimental

    DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which … express high levels of CD-10* or TOP** peptidases, such as prostate cancer, colorectal cancer, melanoma, pancreatic cancer and some types of renal cancer.

  7. Target

    20-ketosteroid reductase (20-hydroxysteroid dehydrogenase)

    go.drugbank.com/bio_entities/BE0009795
    EnzymeHumans and other mammals

    Catalyzes the reduction of estrone into 17beta-estradiol but with low efficiency (PubMed:14672942). … Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 20alpha-hydroxysteroids, but also 3alpha/beta- and 17beta-hydroxysteroids (PubMed:10998348, PubMed

    Synonyms: High-affinity hepatic bile acid-binding protein
  8. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  9. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  10. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults